The Innovative Licensing and Access Pathway (ILAP), launched by the MHRA in 2021 and re-launched in 2025, is helping transform how breakthrough medicines—especially for rare and life-threatening diseases—reach patients faster. It’s a key part of the UK’s strategy to become a global leader in medical innovation.
ILAP offers:
⏰ Accelerated Timelines – Tools like the Innovation Passport streamline regulatory processes, cutting time-to-market significantly.
🤝 Collaborative Engagement – ILAP brings together the MHRA, NICE, and the NHS early to align on evidence and reimbursement—reducing delays and uncertainty.
📊 Flexible Evidence – Adaptive licensing and iterative data submission ease the evidence burden, especially for rare disease therapies.
ILAP allows combined Phase IIb/III trials with a “seamless transition,” so confirmatory data can be generated during regulatory review. That means no more waiting for full Phase III completion to begin the approval process.
Products can’t have entered confirmatory trials (e.g., Phase III) at application. Confirmatory evidence (like Phase 3 data) remains required for full approval.
The process is already delivering real-world impact—the first three treatments are now leveraging ILAP!
This pathway is a major step toward a more agile, patient-centric, and innovation-friendly regulatory ecosystem.
